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DOI 10.1016/j.ccr.2010.06.018SUMMARYRegulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here,
we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key role in the initiation of
mitosis, and regulates the localization of the centrosome linker protein, C-Nap1, through S2392 phosphory-
lation. Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in
interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to
paclitaxel in culture and in xenografts. Depletion of SIK2 also delayedG1/S transition and reduced AKT phos-
phorylation. Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade
serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian
cancers.INTRODUCTION
Uncontrolled mitosis is a distinguishing feature of cancer cells
that has been effectively exploited for cancer therapy using anti-
tubulin drugs such as paclitaxel. The use of primary paclitaxel-
based combination chemotherapy increases progression free
survival and overall survival in hematological and solid malignan-
cies including ovarian cancer (Martin et al., 2008; McGuire et al.,Significance
Taxanes stabilize microtubules, inhibit mitosis, induce apoptos
at many sites including the ovary. The anti-tumor activity of tax
that affect both cell cycle andmitosis. Here we show that SIK2
linker protein C-Nap1 and plays a key role in regulating the on
with paclitaxel in inducing cytotoxicity, whereas higher expr
Independent of its antimitotic role, SIK2 targeting resulted in
Thus, SIK2 provides a multimodal therapeutic target in a subs1996). Whereas high-grade serous ovarian cancers are known to
be highly chemosensitive, a significant proportion of these
cancers fail to respond to primary taxane therapy leading to
the emergence of resistant disease. There is a pressing need
for the discovery of synergistic therapies that may improve
ovarian cancer response to taxane-based chemotherapy and
overall prognosis. Currently available mechanisms for selective
enhancement of taxane response, such as the use of kinesinis, and produce regression in a fraction of cancers that arise
anes might be increased by concurrently regulating kinases
localizes at the centrosome, phosphorylates the centrosome
set of mitosis. SIK2 depletion resulted in profound synergy
ession in ovarian cancers correlated with poor prognosis.
decreased G1/S transition and low AKT phosphorylation.
et of ovarian cancers.
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Figure 1. A Kinome siRNA Screen Identifies Regulators of G2/M
Progression in Ovarian Cancer
(A) A schematic presentation of the siRNA kinome screen.
(B–H) Each of the 779 genes included in the screen was targeted using pools of
four individual siRNAs. These pools were divided into three plates (320 pools
for plates 1 and 2 and 139 pools in plate 3). Three replicates were used for
each plate, and ten images were obtained per well. Integrated nuclear intensity
(INI) values for individual cells, defined as the nuclear area multiplied by its
mean pixel intensity, were extracted from 32,400 images, including a total of
1,946,532 cells. The calculation of the percentage shift of the median inte-
grated nuclear intensity value (ploidy index) is explained in (B–E). Images
were obtained 48 hr after transfection with (B) nontargeting siRNAs or (C)
a pool of siRNAs targeting AURKB. Arrow heads in (C) point to examples of
fused nuclei. Scale bar represents 10 mm. The INI valueswere used to generate
cell-cycle histograms after (D) nontargeting siRNA transfection or (E) AURKB
siRNA transfection. Note the shift to the right of the log2 INI values in (E) as
a consequence of tetraploidy. The ploidy index (PInd) was obtained as the
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110 Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc.motor inhibitors or the inhibition of mitotic exit, are focused on
targeting cancer cells only in mitosis (Huang et al., 2009; Mayer
et al., 1999). Although such strategies have shown clinical
promise, overall tumor response rates have been limited (Blag-
den et al., 2008; Gautschi et al., 2008; Lin et al., 2008; Strebhardt
and Ullrich, 2006). Novel therapeutic targets that augment
taxane effects in inhibiting mitosis while providing taxane-
and mitosis-independent mechanisms of cancer cell death are
needed to improve clinical chemotherapy response. In this
work we conducted an siRNA-based screen to identify modula-
tors of mitotic progression that may influence clinical paclitaxel
response.
RESULTS
A High Content siRNA Kinome Screen Identifies
Cell-Cycle Regulators of Ovarian Cancer Cells
Recent evidence suggests that delayed mitotic progression or
the inhibition of mitotic exit are key predictors of cell death either
with or without taxane treatment (Bekier et al., 2009; Huang et al.,
2009). To identify regulators of mitotic progression in ovarian
cancer cells that may modulate taxane response, we used
a three-step approach: (1) we screened 779 pools of siRNAs
(Dharmacon kinome library) targeting individual genes to identify
potential regulators of the G2 or the M phases (G2/M) of the cell
cycle; (2) several hits were selected for further validation using
individual siRNAs that made up the pool used in the primary
screen; and (3) time-lapse microscopy was used to identify
specific regulators of mitotic progression that were then tested
for synergistic interactions with paclitaxel.
The primary screen used automated image acquisition and
morphometric analysis of fixed cells in 384-well plates (high
content analysis, Figure 1A) to measure single-cell DNA content
after siRNA treatment. The integrated nuclear intensity values
(defined as the nuclear areamultiplied by its mean pixel intensity)
were calculated as a measure for DNA content and used to
generate cell-cycle histograms after the knockdown (KD) of
each of the 779 genes included in the screen. The percentage
of shift of the median integrated nuclear intensity value after
a gene KD compared to that after transfection using nontarget-
ing siRNA was calculated and termed the ploidy index (Figures
1B–1E and Table S1 available online). Genes that on KD induced
a percentage shift (ploidy index) that was above the median and
2 standard deviations (SD) of all genes in a plate were identified
as positive hits for further validation (Figure 1G and Table S2).
There was a high correlation between the ploidy indices across
triplicate plates (median correlation coefficient = 0.74) and
amean coefficient of repeatability for all genes tested of 0.1, indi-
cating high data precision in the screen (Figure 1F, Figure S1A,percentage of the median INI after gene knockdown normalized to the median
INI after control transfection. (F) An example of the correlation between the
ploidy indices of two replicate plates in the screen. In (G), the cutoff PInds
for each plate and examples of the identified hits are shown. (H) The
percentage of the tetraploid cells in relation to the total number of cells after
either paclitaxel treatment, as a positive control for tetraploidy, or knockdown
of genes using four independent siRNAs. The mean ± SD of triplicates is
presented.
See also Figure S1 and Tables S1–S3.
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been previously shown to regulate G2 or M phases of cell-cycle
progression such as cyclin dependent kinase 1 (CDC2) and
polo kinase 1 (PLK1) (Table S2). The magnitude of ploidy shift
varied according to the mechanism of G2/M regulation by
a gene rather than the biological importance. For example,
depletion of Aurora kinase B (AURKB) resulted in cytokinesis
failure and a profound increase in the ploidy index. In contrast,
depletion of the centrosome kinase phosphotyrosine picked
threonine kinase 1 (MPS1, also called TTK) resulted in a modest
increase in ploidy that presumably reflects delayed mitotic tran-
sition (Tables S1–S3).
Among the identified hits, seven were selected for further
validation based on their potential novelty (Figure 1H). To
exclude off-target effects, we used four individual siRNAs that
made up the siRNA pool that was used in the primary screen
to KD each gene and compared the percentage of tetraploid
cells after genetic KD with the percentage after transfection
with a nontargeting siRNA control. As a positive control for
tetraploidy we used (1) paclitaxel treated nontransfected cells
and (2) KD of the chromosome passenger protein Borealin
(CDCA8), which plays a critical role in cytokinesis. Six of the
seven genes were validated with at least 2 independent siRNAs,
which resulted in a significant increase in tetraploidy (p < 0.05,
Wilcoxon test, Figure 1H). Only one of the four siRNAs targeting
the eukaryotic elongation factor-2 kinase (EEF2K) resulted in
increased tetraploidy indicating an off-target effect. Interest-
ingly, this siRNA had a perfect sequence match to EEF2K and
also 70% sequence match to Borealin.
The six validated targets may be involved in the regulation of
G2, mitosis or both. To determine specific regulators of mitosis
we used bright field microscopy and time lapse imaging to
identify targets that lead to delayed mitotic progression. To
demonstrate the opposite effect, we used KD of the mitotic
checkpoint protein BUBR1 and, as expected, this resulted in
rapid mitotic progression (mean = 20 min after KD of BUBR1
compared to 58 min in controls, n = 10, p < 0.01; Movies S1
andS2). In contrast, depletion ofSIK2, cyclin dependent kinase 2
interacting protein (CINP) or CDK5 regulatory subunit 1
(CDK5R1) resulted in a significant delay in mitotic progression
followed by mitotic exit without cell division (Movie S3 and
data not shown).
The finding that SIK2 may play a role in regulating mitosis was
intriguing because its established functional role has been in the
regulation of cellular metabolism but not the cell cycle (Dentin
et al., 2007; Katoh et al., 2004; Screaton et al., 2004). We have
previously shown that KD of the Drosophila orthologs of serine/
threonine kinase 11 (STK11, also called LKB1), a known SIK2
kinase, and SIK3, an immediate family member of SIK2 results
in severe mitotic abnormalities (Bettencourt-Dias et al., 2004).
We, therefore, selected SIK2 for further validation. Time-lapse
photography showed that loss of SIK2 resulted in a dramatic
increase in the mean mitotic progression time (62 min in control
cells transfected with nontargeting siRNA versus 133, 209, and
172 min after SIK2 KD using three siRNAs, p < 0.001, one-way
ANOVA and Tukey’s multiple comparisons test) (Figures 2A–
2D). Importantly many of the SIK2 depleted cells either did not
exit mitosis during the time of recording, ruptured or failed to
undergo cytokinesis (Movie S3 and data not shown).Depletion of SIK2 Sensitizes Ovarian Cancers
to Paclitaxel
As depletion of SIK2 resulted in protracted mitotic progres-
sion time, we tested the hypothesis that this may sensitize
ovarian cancer cells to paclitaxel. Transfection with SIK2 siRNA
decreased the dose of paclitaxel required to reduce cancer cell
growth by 50% (GI 50) from 4.8 nM (95%confidence interval [CI]:
2.7–8.4 nM) in control-transfected cells to 1.4 nM (95% CI:
0.6–3.2 nM), 0.17 nM (95% CI: 0.05–0.6 nM), or 0.36 nM (95%
CI: 0.01–0.1 nM) for SIK2 siRNAs A, B, and C, respectively
(Figure 2E). Importantly, this effect was not cell specific as
SIK2 KD significantly decreased paclitaxel GI 50 in Hey cells
(from 7.8 nM for control siRNA to 2.3 nM for SIK2 siRNA), ES2
cells (from 6.7 nM for control siRNA to 3.3 nM for SIK2 siRNA)
and 2008 cells (from 0.67 nM for control siRNA to 0.47 nM for
SIK2 siRNA) (Figure 2F), indicating that selective depletion of
SIK2 is sufficient to sensitize ovarian cancer cells to paclitaxel
in vitro.
To test the biological significance of SIK2 in ovarian cancer we
first examined its expression pattern in 59 ovarian cancers and
nine pools of normal ovarian surface epithelial cells using quan-
titative PCR. The range of expression of SIK2 was narrow sug-
gesting that a large number of cases was required to identify
a correlation between SIK2 expression and clinical outcome
(data not shown). The importance of SIK2 in regulating mitosis
and paclitaxel response was supported by the analysis of SIK2
expression in 229 patients with high-grade serous (HGS) ovarian
cancers in a population-based study (Tothill et al., 2008). Higher
expression of SIK2 significantly increased the hazard of cancer
progression after taxane-based chemotherapy using the two
independent affymetrix microarray probe sets that were found
to accurately represent SIK2 expression (Figure 2G and Fig-
ure S2A). These results were validated using quantitative PCR
(Figure S2B). In addition, the level of SIK2microarray expression
in paclitaxel or carboplatin resistant ovarian cancers was
compared to that in paclitaxel or carboplatin responders in
a prospective randomized clinical trial in which patients with
primary ovarian cancer were treated initially with either single
agent paclitaxel or single agent carboplatin for three cycles
(Ahmed et al., 2007). SIK2 expression was significantly higher
in paclitaxel resistant compared to paclitaxel-sensitive cancers
(p = 0.028, one-sided t test, n = 20; Figure S2C). In contrast,
no significant difference was found in SIK2 expression between
carboplatin resistant or carboplatin sensitive cancers (p = 0.7,
one-sided t test, n = 15; Figure S2C). All together these data
support an important role of SIK2 in the regulation of mitosis
and taxane response in cell culture and in ovarian cancer
patients.
SIK2 Localizes at the Centrosome
To investigate a possible physical association between SIK2
and the mitotic spindle, we examined the subcellular localization
of SIK2 using immunofluorescence (IF). As previously described,
endogenous SIK2 was observed in the cytoplasm (Katoh et al.,
2004). In addition, SIK2 colocalized with g-tubulin in the
centrosomes of 70% of cells in interphase and in all cells in
mitosis and coimmunoprecipitated with g-tubulin (Figure 3A
and Figure S3A). Preincubation of the SIK2 antibody with
recombinant SIK2 protein, but not with control proteins (BSACancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc. 111
Figure 2. Depletion of SIK2 Delays Mitotic
Progression and Sensitizes Ovarian Cancer
Cells to Paclitaxel
(A–D) SKOv3 cells were transfected with either (A)
nontargeting siRNA or (B) SIK2 siRNA for 48 hr
then monitored for 16 hr (one image every 5 min)
using bright field phase-contrast microscopy.
The time interval from nuclear envelope break-
down (0:00 in A and B) to anaphase onset (01:20
in control cells) was estimated. Arrows point to
the cell under study. Time is shown as hr:min.
Scale bar represents 10 mm. In (C), western blot
confirmation of knockdown of SIK2 using three
independent siRNAs compared to nontargeting
siRNA control is shown. r-GST-SIK2; recombinant
GST-tagged SIK2 was used on the same western
blot to confirm the antibody specificity. (D) The
mean ± SEM of the mitotic transition time
(obtained as in A and B) is presented after control
and SIK2 siRNA transfections.
(E) SKOv3 cells (5000 cells per well) were reverse
transfected in 96-well plates using either nontar-
geting controls or SIK2 siRNAs (A), (B), and (C)
for 24 hr and cells were then either (a) fixed and
stained using crystal violet to estimate the number
of cells on the day of paclitaxel treatment (day 0);
or (b) treated with either diluent or paclitaxel at 9
different concentrations. The latter group of cells
was fixed and stained 72 hr after drug treatment.
Growth of cells from day 0 to day 3 was estimated
and the percentage paclitaxel-induced growth
inhibition for each siRNA in relation to diluents-
treated cells transfected with the same siRNA
was calculated and a least-squares fit was
obtained to estimate the GI 50 as described in
Experimental Procedures (Monks et al., 1991).
Shown is the mean ± SEM from three replicates
per concentration.
(F) The effect of depletion of SIK2 using siRNA C
on paclitaxel response in three cell lines is shown.
The experiment was conducted as in (E). Shown is
the mean ± SEM from six replicates per concen-
tration. Also shown is the p value for the compar-
ison between the GI 50 in cells transfected with
nontargeting siRNA control versus cells trans-
fected with SIK2 siRNA.
(G) Microarray expression data for two probe sets representing SIK2were used to generate Kaplan-Meier survival curves for high expressing (defined as cancers
with values above the median + (0.5 3 median absolute deviation [MAD]) or low expressing (below the median  (0.5 3MAD) for 229 high-grade serous (HGS)
ovarian cancers.
See also Figure S2 and Movies S1–S3.
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SIK2 on IF (Figure S3B). Further confirmation of specificity was
achieved by showing that KD of SIK2 resulted in a significant
decrease in the percentage of cells with detectable SIK2 in the
centrosome using immunofluorescence (p < 0.001, t test; Fig-
ure S3C). The expression of SIK2was predominantly pericentrio-
lar as evidenced by immunostaining of HeLa cells that stably
expressed GFP-tagged centrin (Figure S3D) and was indepen-
dent of microtubules because it colocalized with g-tubulin
after nocodazole treatment (data not shown). The observation
that endogenous SIK2 localized at centrosomes was further
supported by showing that exogenous myc/flag-tagged SIK2
localized to the centrosomes of 50% of the cells examined (Fig-
ure 3B). In addition, differential centrosome localization was also112 Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc.observed after transfection using the untagged version of
the SIK2 plasmid and detection using anti-SIK2 antibody
(p < 0.001, paired t test; Figures S3E–H). All together, these
results confirm that a pool of SIK2 localizes at the centrosome.
SIK2 Induces Centrosome Splitting
We next tested the functional role of SIK2 in the centrosomes.
Examination of the centrosomes in interphase cells transfected
with a myc/flag-SIK2 expression construct revealed a significant
increase in the percentage of myc-positive cells with centro-
some splitting (CS) compared to the percentage in myc-negative
cells or cells transfected with empty vectors (21.3, 5, and 3.9,
respectively; p < 0.001, one-way ANOVA; Figures 4A–4C).
This effect was not due to failure of re-engagement after
Figure 3. SIK2 Localizes at the Centrosome
(A) SKOv3 cells were fixed and stained for immu-
nofluorescence (IF) using the indicated antibodies
to show the colocalization between SIK2 and
g-tubulin.
(B) The colocalization of ectopically expressed
myc-tagged SIK2 with g-tubulin in SKOv3 cells is
shown. Also note the pericentrosomal expression
of SIK2. Scale bar represents 5 mm. See also
Figure S3.
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for centriole duplication (Tsou and Stearns, 2006) as in SKOv3
cells disengaging centrioles only separate by submicrometer
distances (Figures S4A–S4G). SIK2-induced CS was dependent
on its kinase activity because overexpression of a kinase-
inactive SIK2 mutant (SIK2_mt; K49M) (Katoh et al., 2006) did
not result in an increase in the percentage of cells with CS
(Figures 4B and 4C). The effect of wild-type SIK2 in inducing
CS was similar to the reported phenotype that is observed after
the overexpression of NEK2 but less in magnitude (3.9% in
control cells versus 21.3% in SIK2-positive cells and 50.9% in
NEK2-positive cells, p < 0.001; Figures 4B and 4C). Similar
results were observed in the osteosarcoma cell line U2OS,
a cell line that is commonly used to study this phenotype
(4, 29, and 55 for cells transfected with empty vector, SIK2-
myc/flag, and NEK2-myc/flag, respectively; p < 0.001, one-
way ANOVA; Figure 4C). As the metabolic function of SIK2 is
activated after LKB1-induced phosphorylation, we tested the
effect of coexpression of SIK2 and LKB1 on CS. LKB1 did not
increase the percentage of cells with CS above what is already
achieved by SIK2 alone (Figure S4H). This implies that the
activity of SIK2 in inducing centrosome splitting is independent
of LKB1.
We next took an unbiased approach to identify possible
targets for SIK2 phosphorylation in the centrosome. Searching
the Swiss-PROT database for human proteins that contains
the previously identified putative SIK2 phosphorylation con-
sensus sequence LX[HKR]S/TXSXXXL (Screaton et al., 2004),
identified the peptide LHHSLSHSLL in the carboxy-terminal
domain (amino acids: 2387–2396) of the centrosome protein
CEP250 (also called C-Nap1) as a putative phosphorylation
site. C-Nap1 is thought to be one of the key proteins that are
required for centrosome cohesion in interphase and its centro-
some localization is predominantly regulated by phosphorylationCancer Cell 18, 109–121(Fry et al., 1998a; Mayor et al., 2002).
Importantly, phosphorylation of the car-
boxy-terminal part of C-Nap1 by ectopi-
cally expressed NEK2 results in prema-
ture exit of C-Nap1 from the centrosome
and CS (Fry et al., 1998a, 1998b; Mayor
et al., 2002). Recombinant SIK2 directly
phosphorylated a 15 amino-acid peptide
derived from C-Nap1 that contained
the putative SIK2 phosphorylation site
at the underlined serine amino acids
(LAGLHHSLSHSLLAV) in vitro as shown
by liquid chromatography-mass spec-trometry (LC-MS), data not shown. In addition, SIK2 catalyzed
the incorporation of radioactive g-32p-ATP into recombinant
GST-tagged carboxy-terminal C-Nap1 (GST-C-Nap1-ct, aa;
1982–2442; 461 amino acids), but not GST alone (Figure 4D).
Remarkably, LC-MS confirmed that the predominant serine
phosphorylation site of the recombinant carboxy-terminal
domain of C-Nap1 is S2392 at the predicted consensus
phosphorylation sequence and to a lesser extent S2394
(LHHSLSHSLL). Importantly, SIK2 phosphorylation of carboxy-
terminal C-Nap1 appeared highly specific as the peptide
LHHSLSHSLL was the predominant site of serine phosphoryla-
tion in addition to a second site (S2234) at the fifth potential
coiled coil region of C-Nap1 (Figure 4E). We next expressed
a protein A-tagged version of the carboxy-terminal domain of
C-Nap1 in 293-T cells, which are known for their high transfec-
tion efficiency. Immunoprecipitation using rabbit IgG-coated
beads of protein A-tagged carboxy-terminal C-Nap1 but not
protein A alone coprecipitated endogenous SIK2 (Figure 4F) indi-
cating that direct binding between SIK2 and exogenously
expressed carboxy-terminal part of C-Nap1 occurs in cells. In
addition, endogenous SIK2 partially colocalized with ectopically
expressed C-Nap1 in the centrosome of SKOv3 cells (Fig-
ure S4I). Co-expression of full length C-Nap1 with the kinase
active SIK2 in 293-T cells resulted in the phosphorylation of
C-Nap1 as detected by C-Nap1 immunoprecipitation followed
by probing using anti-phosphoserine antibody. In contrast
expression of the kinase mutant SIK2 did not result in phosphor-
ylation of the coexpressed C-Nap1 (Figure 4G). We next investi-
gated whether SIK2 displaces C-Nap1 from the centrosomes.
IF confirmed the localization of endogenous C-Nap1 at the
centrosomes of ovarian cancer cells and, in addition, showed
that there was variability in the centrosome expression level
(Figure S4J). Knockdown of C-Nap1 resulted in a 10-fold
increase in SKOv3 cells with centrosome splitting (Figure S4K)., August 17, 2010 ª2010 Elsevier Inc. 113
Figure 4. Overexpression of SIK2 Induces
Centrosome Splitting through Phosphoryla-
tion of C-Nap1
(A) SKOv3 cells were transfected with myc/flag-
tagged wild-type SIK2 or myc/flag-tagged kinase
mutant SIK2 (SIK2_mt) plasmid for 24 hr then cells
were fixed and stained using anti-myc antibody
(red), and anti-g-tubulin antibody (green). Arrows
show an example of CS (intercentrosome dis-
tance > 2 mm) after SIK2 transfection.
(B and C) Mean ± SEM of the percentage of cells
with CS 24 hr after transfection using the indicated
plasmids. Overexpression of NEK2, which is
known to induce CS, was used as a positive
control in this experiment. Experiments were per-
formed at least in triplicates. Scale bar represents
5 mm.
(D) In vitro kinase assays were performed in the
presence of either g-32P-ATP followed by autora-
diography (left), or ATP alone followed by Coo-
massie staining (right). The bands representing
GST-C-Nap1-ct were cut and subjected to
LC-MS analysis for protein identification and to
detect sites of phosphorylation.
(E) A diagram showing the potential five coiled coil
domains of C-Nap1 as predicted in the Uniport
data base and the serine phosphorylation sites de-
tected by LC-MS at amino acids S2234, S2392,
and S2394.
(F) Either Protein A alone or Protein A-tagged
C-Nap1-ct were transiently expressed in 293-T
cells then immunoprecipitated using Rabbit IgG
coated beads followed by elution and separation
of the precipitates using SDS-PAGE and immuno-
blotting using anti-SIK2 antibody.
(G) 293T cells were transfected with the indicated
plasmids for 24 hr, then lysates were collected and
immunoprecipitation (IP) performed using the
indicated antibodies. Immunoprecipitates were
resolved by electrophoresis as described in
methods then probed with pan anti-phosphoser-
ine antibody initially then anti-C-Nap1 antibody
using the same membrane. Also shown is the
immunoblot result for SIK2 performed on the
same membrane.
(H) Cells were cultured in 384-well plates overnight
then fixed and stained using Hoechst nuclear stain and anti-C-Nap1 antibody. Shown is the automated analysis of 4000 cells over 10 replicate wells (as described
in Supplemental Experimental Procedures) to identify cell-cycle histograms, mean centrosome intensity value for C-Nap1 ± SEM and the percentage of cells with
undetectable C-Nap1 in the centrosomes. Mitotic cells were manually excluded from the analysis.
(I)Cellswere transfectedwithSIK2expressingconstruct for24hr thenfixedandstainedusing the indicatedantibodies.Note the lowerC-Nap1 intensity in thecentro-
somesof (1)SIK2-transfected cell compared to (2) untransfectedcell in the samefield. Scale bar represents 5mm.Arrowspoint tomagnifiedcentrosome in the inset.
(J) Shown is the percentage of cells with undetectable C-Nap1 centrosome signal per cell-cycle stage after transfection using the indicated plasmids.
See also Figure S4.
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that its centrosome localization significantly increases in G2
compared to G1/S (p < 0.001, t test; Figure 4H). In addition,
the percentage of cells in which the centrosome expression of
C-Nap1 was below the automated threshold of detection
decreased from 22% in G1/S to 13% in G2. We next examined
the effect of SIK2 transfection on the centrosome localization
of C-Nap1 (Figure 4I). SIK2 transfection resulted in a modest
but significant increase of the percentage of cells with undetect-
able C-Nap1 signal in G1 (22% in SIK2 negative, 27.2% in SIK2
positive, p < 0.001, c2 test, n = 3376; Figure 4J). However, in G2,
SIK2 expression resulted in a greater magnitude of C-Nap1114 Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc.displacement (14.5% in SIK2 negative cells to 29.4% in SIK2
positive cells; p = 0.004; c2 test, n = 340; Figure 4J). In contrast,
expression of a kinase inactive SIK2 did not increase the
percentage of cells with undetectable C-Nap1 signal in G1/S
or in G2 (Figure 4J). These results implicate C-Nap1 as a putative
downstream target for SIK2 at the centrosome.
SIK2 Is Required for Centrosome Separation in Mitosis
As ectopic expression of SIK2 resulted in CS, we tested the
hypothesis that endogenous SIK2 was required for centrosome
separation in mitosis. Interestingly, in interphase, depletion of
SIK2 resulted in uncoupling of the centrosomes from the nucleus
Cancer Cell
SIK2 Is a Centrosome Kinase and a Therapy Target(Figures S5A and S5B). Importantly, cotransfection of SKOv3
cells with siRNA targeting the 30UTR of SIK2 and a construct
expressing the open reading frame of SIK2 completely rescued
this phenotype (Figure S5C). Inducing a wound in a confluent
monolayer of SKOv3 cells after control siRNA transfection
oriented the centrosomes toward the leading edge of the cell.
In contrast, cells depleted from SIK2 failed to orient their centro-
somes toward the leading edge in spite of the formation of lamel-
lipodia (Figures S5D and S5E). These results further support the
notion of a centrosome-specific function of SIK2. In mitosis,
depletion of SIK2 resulted in the accumulation of cells in prome-
taphase within 48 hr of transfection (p < 0.01, t test; Figures 5A
and 5B). Importantly, this mitotic defect was not because of
depletion of energy reserves as knockdown of SIK2 did not
decrease cellular ATP content (Figure S5F). There was a sig-
nificant increase in the ratio of prometaphase to metaphase
cells after SIK2 KD (2.1 in controls and 8.3 after SIK2 KD; Fig-
ure 5C). These results were confirmed in the U2OS osteosar-
coma cell line (Figure 5D). The block in prometaphase was due
to failure of SIK2-depleted cells to form bipolar mitotic cells
(p < 0.001, one-way ANOVA; Figures 5A and 5E). Importantly,
the role of SIK2 in regulating centrosome separation in mitosis
was evolutionarily conserved, as depletion of the ortholog of
SIK2 in Drosophila (CG4290) in DMEL cells resulted in a signifi-
cant increase in mitotic cells with defects in centrosome separa-
tion (p < 0.01, t test; Figures 5F and 5G). Thus, SIK2 is required
for appropriate centrosome positioning in interphase and for
centrosome separation in mitosis.
PRKAR2A Inhibits SIK2 in the Centrosome
We next investigated the mechanisms regulating SIK2 activity in
the centrosome. Themetabolic function of SIK2 in the cytoplasm
is under inhibitory control by PKA (Katoh et al., 2004). Interest-
ingly, the regulatory subunit of PKA, PRKAR2A, is tethered at
the centrosome and the pericentriolar region of interphase cells
by the anchoring protein AKAP450 (Carlson et al., 2001; Land-
sverk et al., 2001). In mitosis, CDC2 phosphorylates PRKAR2A
resulting in its displacement from the centrosome (Carlson
et al., 2001). Consistent with previous observations, we found
that PRKAR2A localized to the centrosomes of SKOv3 cells in
interphase. In addition, PRKAR2A disappeared from the centro-
some early in prophase and this coincided with centrosome
separation and a significant increase in the centrosome level of
SIK2 and g-tubulin (p < 0.001, one-way ANOVA; Figures S6A–F).
The centrosome localization of PRKAR2A was required
for maintaining centrosome pairing because its depletion in
SKOv3 cells resulted in 11.6-fold increase in interphase cells
with centrosome splitting compared to control siRNA trans-
fected cells (9.3% and 0.8% respectively; p < 0.001, t test;
Figure S6G). To target the centrosome localization of PRKAR2A
without interfering with its cytoplasmic level we depleted
AKAP450 in SKOv3 cells (Figure 6A). This depletion abolished
the centrosome localization of PRKAR2A but not that of SIK2
(Figure S6H) and resulted in a significant increase in cells with
centrosome splitting (CS) (10.8% in AKAP450 depleted cells
versus 1.3% in controls; p < 0.001, one-way ANOVA; Figure 6B).
Similar results were obtained using two other AKAP450 siRNAs,
not shown, Importantly, the increase in CS was dependent on
SIK2 because cotransfection of SKOv3 cells with siRNAs target-ing SIK2 and AKAP450 rescued the phenotype (Figure 6B). Thus
PRKAR2A is required for preventing SIK2 from inducing CS
in interphase and may play a key role in regulating the appro-
priate timing of centrosome separation early in mitosis.
SIK2 Is Required for AKT Phosphorylation and Growth
of Ovarian Cancer Cells
We next investigated the effect of SIK2 depletion on cancer cell
growth independent from paclitaxel. Depletion of SIK2 in the
ovarian carcinoma cell lines SKOv3, ES2, and Hey resulted in
a significant decrease in cancer cell proliferation (Figure 7A,
p < 0.001, t test). To investigate the mechanism of suppression
of proliferation we tested the effect of depletion of SIK2 on the
cell cycle with or without synchronization. Cell-cycle analysis
using flow cytometry of nonsynchronized population of SKOv3
cells after depletion of SIK2 confirmed the accumulation of
tetraploid cells (Figure 7B). However, synchronization of cells
in G2/M using paclitaxel treatment after SIK2 depletion showed
that a significant proportion of cells were delayed in G1 (Fig-
ure 7B) and failed to enter mitosis as indicated by the significant
decrease in mitotic index after paclitaxel treatment (p < 0.001,
one-way ANOVA; Figure 7C). These data indicated that loss of
SIK2 results in defective G1/S transition in addition to delayed
mitotic progression and that both may contribute to suppression
of ovarian cancer cell proliferation. To investigate the molecular
profile underlying delayed G1/S transition we investigated the
effect of SIK2 depletion on the expression of 139 proteins using
reverse phase protein arrays. Depletion of SIK2 resulted in a
significant decrease in AKT phosphorylation at amino acid 473
without significantly influencing total AKT expression (Figure 7D).
We next examined the effect of SIK2 depletion using three inde-
pendent siRNAs in three ovarian cancer cell lines on the of
expression of 139 proteins and correlated this with cancer cell
growth for the cell lines tested, nine expression values for
each protein correlated with nine growth proliferation values
(Figure 7E and Table S4). Decreased phosphorylation of AKT
after SIK2 depletion resulted in the highest direct correlation
with suppression of ovarian cancer cell growth (Pearson’s corre-
lation coefficient = 0.83, p = 0.006; Figure 7F). In contrast, deple-
tion of SIK2 resulted in increased LKB1 expression and this
significantly correlated with suppression of ovarian cancer cell
growth, i.e., a strong negative correlation (Pearson’s correlation
coefficient = 0.82, p = 0.007).
Loss of SIK2 Sensitizes Ovarian Cancer to Paclitaxel
In Vivo
Based on the above findings, we proposed that depletion ofSIK2
interferes with G1/S progression leading to apparent early resis-
tance to paclitaxel-induced apoptosis due to decreased pacli-
taxel-induced mitotic arrest (Figure 7C and Figure S7). We
hypothesized that cells escaping from G1/S after SIK2 depletion
fail to undergo centrosome separation and that this leads to
sensitization to paclitaxel-induced cytotoxicity. To test this
hypothesis we used two orthotopic models of ovarian cancer
metastasis (SKOv3ip and HeyA8 cancer cells) and in vivo SIK2
KD using neutral nanoliposomal (DOPC) delivery of siRNA
(Figures 8A and 8B). As expected, depletion of SIK2 resulted in
a significant decrease in the mitotic index 24 hr after paclitaxel
treatment (p < 0.001, t test, Figures 8C and 8D). However,Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc. 115
Figure 5. SIK2 Is Required for Centrosome Separation in Mitosis
(A–E) Cancer cells were transfected with siRNAs for 48 hr as indicated then fixed and stained. In (A) and (B), SKOv3 cells were stained using anti-g-tubulin (red)
and anti-phosphohistoneH3 (green) to reveal the centosome position inmitosis in relation to chromosomes. Note the presence of examples from different mitosis
phases in control cells (1–4: prophase, prometaphase, metaphase, and anaphase, respectively) compared to the predominance of prometaphase cells after SIK2
KD. Also shown are examples of multipolar (I) and monopolar (II) centrosome positioning after SIK2 KD. Bar plots in (B) and (D) represent the mean ± SD of the
percentages of cells at different stages of mitosis. Bar plots in (C) represent the mean prometaphase/metaphase ratio ± SD.
(F andG) DMELDrosophila cells were transfected using nontargeting control double-stranded RNA (dsRNA) or dsRNAs targeting theDrosophila ortholog of SIK2.
Examples of mitotic cells with failed centrosome separation are presented in (F). In (G), the mean ± SD of mitotic cells with failed centrosome separation from
three independent experiments is shown. Scale bars represent 10 mm.
See also Figure S5.
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SIK2 Is a Centrosome Kinase and a Therapy TargetSIK2 KD resulted in a significant increase in monopolar mitotic
cells (p < 0.001, Figures 8E and 8F) and a significant decrease
in tumor weight after paclitaxel treatment compared to nontar-116 Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc.geting control siRNA-DOPC treated with paclitaxel (p = 0.008
and 0.005 for SKOv3ip and HeyA8 models, respectively; t test;
Figures 8G and 8H). Depletion of SIK2, independent from
Figure 6. Centrosome Localization of
PRKAR2A Is Required for Regulating the
Appropriate Timing of Centrosome Separa-
tion by SIK2
(A) SKOv3 cells were transfected with the indi-
cated siRNAs for 72 hr, then fixed and stained.
The centrosome expression of PRKAR2A is
present in control cells (arrow) but absent after
KD of AKAP450 (I and II).
(B) Bar plots represent the mean ± SD of triplicate
percentages of cells with CS after transfection
with the indicated siRNAs. Depletion of AKAP450
resulted in a significant increase in CS, whereas
codepletion of AKAP450 and SIK2 rescued this
phenotype.
Scale bar represents 5 mm. See also Figure S6.
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SIK2 Is a Centrosome Kinase and a Therapy Targetpaclitaxel, resulted in a modest decrease in tumor weight in the
SKOv3ip model (p = 0.2) and a modest but significant decrease
of tumor weights in the HeyA8 model (p = 0.02). Taken together,
these results confirm the effect of loss of SIK2 in inducing
synergy to paclitaxel in vitro and in vivo.
DISCUSSION
We have previously shown that LKB1, a master kinase for all
members of the AMPK superfamily, plays an important role in
regulating mitosis through mechanisms that remained unclear
(Bettencourt-Dias et al., 2004). In this work, we believe we
have identified a previously unrecognized role for SIK2, a
member of the AMPK family in regulating centrosome separation
during mitosis. The effect of depletion of SIK2 on mitosis and
centrosome function is unlikely to be secondary to depletion of
energy reserves. Previous work has shown that the key role
that SIK2 plays in metabolism is in regulating energy balance in
refeeding from starvation (Dentin et al., 2007; Ryu et al., 2009;
Wang et al., 2008). During fasting ATP depletion leads to PKA
activation that inhibits SIK2 resulting in dephosphorylation of
its cytoplasmic target TORC2 and its accumulation in the
nucleus. Nuclear TORC2 enhances CREB-mediated gluconeo-
genesis in an effort to increase ATP production to maintain its
intracellular level. On refeeding from starvation, rising ATP levels
lead to inactivation of PKA and this results in SIK2 activationCancer Cell 18, 109–121leading to phosphorylation of TORC2
and its cytoplasmic retention and degra-
dation. This results in inhibition of gluco-
neogenesis and decreased ATP produc-
tion through this pathway. Thus, based
on this evidence depletion of SIK2 would
not be expected to lead to loss of intracel-
lular ATP under normal feeding condi-
tions. Indeed, work in Drosophila has
shown that depletion of the ortholog of
SIK2 results in enhanced resistance to
metabolic stress in neurons (Wang et al.,
2008). We have also shown here that
depletion of SIK2 did not result in
decreased ATP levels in SKOv3 cells.
Therefore, loss of ATP cannot explainthe mitotic phenotypes that we have observed after SIK2
depletion.
We propose that displacement of PRKAR2A from the centro-
some in prophase relieves SIK2 from inhibition. This molecular
event coupled with higher centrosome expression of SIK2 at
the onset of mitosis may initiate centrosome separation by
inducing additional phosphorylation of centrosome linker pro-
teins such as C-Nap1. We speculate that NEK2 may induce
subthreshold phosphorylation of C-Nap1 and that optimal phos-
phorylation is achieved at the onset of mitosis by the activity of
SIK2. These molecular events could complement the known
decrease in phosphatases, such as PP1a, that oppose NEK2
activity before the onset of mitosis (Meraldi and Nigg, 2001).
Our findings add further proof to the emerging evidence of
coupling cancer cell metabolism and mitosis functions of the
AMPK family members.
It is important to note that SIK2 is a rare example of a thera-
peutic target that on depletion results in mitosis-dependent
synergy with paclitaxel as well as G1/S arrest and decreased
cancer growth independent from taxanes. It is becoming clearer
that regimens involving combination therapies targeting different
phases of the cell cycle are desirable for optimal cancer
response. Several microtubule-independent mitotic inhibitors
have been tested in early clinical trials with or without taxanes.
The results from these trials are still emerging but such
approaches have so far resulted in disease stabilization or partial, August 17, 2010 ª2010 Elsevier Inc. 117
Figure 7. SIK2 Is Required for AKT Phosphorylation and Growth of Ovarian Cancer Cells
(A) SKOv3, ES2, and Hey cells were either transfected using nontargeting control siRNA or the indicated SIK2 siRNAs for 5 days. Cells were fixed and stained
using crystal violet. Shown is the mean ± SEM of 12 replicate values per siRNA transfection type from two independent experiments in SKOv3 cells. **p < 0.001.
Error bars for Hey and ES2 cells represent the SEM of six replicate values per siRNA transfection type from two independent experiments.
(B) Typical cell-cycle distributions are presented after transfection of SKOv3 cells with the indicated siRNAs.
(C) Cells were transfected using the indicated siRNA for 48 hr then treated with paclitaxel 100 nM for 24 hr, fixed, and stained using antiphosphohistone H3 anti-
body to calculate the mitotic index (MI) using flow cytometry. Shown is the mean MI (±SD) of two independent experiments.
(D) Cell lines were transfected with the indicated SIK2 siRNAs and control nontargeting siRNAs for 48 hr, then harvested for analysis of protein expression using
reverse phase protein arrays. Shown is the fraction of expression of AKT-pS437 and total AKT after SIK2 siRNA transfection relative to protein expression after
nontargeting siRNAs.
(E) The expression of 139 proteins (Table S4) was estimated using reverse phase protein arrays as in (D) after transfection of cancer cells using three SIK2 siRNAs
and one nontargeting control in three cell lines: SKOv3, Hey, and ES2. The expression of each of the 139 proteins was correlated with cancer cell growth that was
measured in (A). Each bar represents the coefficient of the correlation between the expression of each of the proteins in nine cell lines (3SIK2 siRNAs3 3 cell lines)
and the growth of the cancer cell line from which the protein was measured. Positive values indicate that higher expression of a protein correlates with more
cancer cell growth. Negative values indicate that higher expression correlate with poor growth.
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Figure 8. Loss of SIK2 Sensitizes Ovarian
Cancer Cells to Paclitaxel In Vivo
(A) A flow diagram showing the design of the
in vivo experiment.
(B) Immunohistochemical confirmation of SIK2
depletion in SKOv3ip1 tissue sections using anti-
SIK2 antibody. Scale bar represents 50 mm.
(C–F) Tumor sections (5 mm) were stained using
the indicated antibodies. (C and D) Sections
were stained using the indicated antibodies to
calculate the mitotic index per field by manually
counting phospho-Histone H3 positive nuclei
and total number of nuclei. Shown in (C) is the
mean ± SEM of the MIs from seven fields from
two mice. In (E), an example of monopolar centro-
some orientation after SIK2 KD in mice is shown.
(F) Bar plot representation of the mean ± SEM of
the percentage of mitotics with monopolar centro-
some orientation from two mice (two slides per
mouse).
(G and H) Mean tumor weights (±SD) obtained
from 10 mice per siRNA type in SKOv3 cells and
Hey cells. Scale bar represents 10 mm.
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SIK2 Is a Centrosome Kinase and a Therapy Targetresponses (Blagden et al., 2008; Gautschi et al., 2008; Perez de
Castro et al., 2008; Strebhardt and Ullrich, 2006). Targeting SIK2
may offer inhibition of cancer cell growth by targeting multiple
phases of the cell cycle. Using reverse phase protein arrays we
showed that SIK2 is required for phosphorylation of AKT at(F) Shown are the regression lines for the correlation between the fraction of ovarian cancer cell proliferation a
and the fraction expression of AKT-pS437 or total AKT after SIK2 depletion relative to nontargeting controls
See also Figure S7 and Table S4.
Cancer Cell 18, 109–121S473 and this may contribute to the de-
layed cell-cycle progression. Another
possible contributing factor is the centro-
some abnormalities after SIK2 depletion
in interphase. It is well documented
that the centrosome functions as a dock-
ing site for several proteins involved in
cell-cycle progression (Matsumoto and
Maller, 2004). Centrosome dysfunction
after loss of key centrosome proteins
or centrosome displacement results in
severe G1 arrest (Hinchcliffe et al., 2001;
Keryer et al., 2003; Khodjakov and
Rieder, 2001; Matsumoto and Maller,
2004). We have shown that loss of SIK2
results in profound abnormalities in
centrosome position, and function that
may be the underlying cause for the
observed G1 arrest.
An important consideration for exam-
ining the potential therapeutic role of
SIK2 will be to test the toxicity profile after
its inhibition. This could be achieved in
mouse models of ovarian cancer metas-
tasis using SIK2 inhibitors. To our knowl-
edge, no specific inhibitors for SIK2 are
currently available. Future work focusingon resolving the structure of SIK2 to inform the development of
inhibitors in parallel with running small-molecule inhibitor
compound screens will be important to identify prototype inhib-
itors of SIK2. The work shown here provides extensive pheno-
typic and biochemical data to support the development offter SIK2 depletion relative to nontargeting control
.
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SIK2 Is a Centrosome Kinase and a Therapy TargetSIK2 inhibitors. Such inhibitors will be highly valuable for further
testing of the biological and therapeutic potential of SIK2 and for
examining its toxicity profile in vivo. It is important to consider
that in mammals SIK2 plays a role in regulating energy balance
in subcutaneous fat on refeeding from starvation. However, its
role in maintaining energy reserves under normal feeding condi-
tions remains unclear. Therefore, whether its inhibition under
normal feeding conditions will result in energy imbalance and
consequent toxicities remains to be tested in animal models.
In this work we showed that the expression level of SIK2
correlated with prognosis in patients with ovarian high-grade
serous cancers and with paclitaxel response. In addition we
showed that the expression level of SIK2 did not correlate with
carboplatin response in the context of a prospective randomized
study. Furthermore, our data in vitro and in xenograft models
show a clear relationship between the intracellular levels of
SIK2 and response to paclitaxel. However, this work does not
exclude the possibility of an effect of SIK2 on response to non
anti-tubulin agents. It will be interesting to investigate the effect
of SIK2 on response to other chemotherapeutic agents in vitro
and in clinical samples in future studies. Regulation of SIK2
might also potentiate targeted therapies. Knockdown of SIK2
was shown to inhibit phosphorylation and activation of AKT
that might be put to use in overcoming paradoxical activation
of AKT by partial mTOR inhibitors such as rapamycin (O’Reilly
et al., 2006).
In summary, we believe this work identifies a previously unrec-
ognized role of SIK2 in regulating cell-cycle progression and
suggests SIK2 as an attractive target for treatment in a proportion
of ovarian cancers that overexpress this protein.EXPERIMENTAL PROCEDURES
Automated Image Acquisition, Segmentation, and Analysis
Automated image acquisition and analysis were performed using the
In Cell Analyzer 1000 and the In Cell investigator software, respectively
(GE Healthcare).
The Australian Ovarian Cancer Study
This was a population-based, multicenter translational study that comprised
prospective collection of biospecimens, clinical, and epidemiological data
from patients with primary epithelial ovarian, primary peritoneal, and fallopian
tube cancer diagnosed between 2001 and 2005. All patients were prospec-
tively consented using a protocol approved by human research ethics commit-
tees at multiple participating clinical and research centers. Further details of
the AOCS cohort can be found at http://www.aocstudy.org and in the Supple-
mentary Experimental Procedures.
In Vivo Experiments in Mice
All mouse experiments were approved by the Institutional Animal Care and
Use Committee of the University of Texas MD Anderson Cancer Center.
Mice were cared for in accordance with guidelines set forth by the American
Association for Accreditation of Laboratory Animal Care and the U.S. Public
Health Service Policy on Human Care and Use of Laboratory Animals. Female
nudemice were inoculated with ovarian cancer cell lines (HeyA8 or SKOV3ip1)
into the peritoneal cavity. After 1 week, SiRNA was incorporated in DOPC-
nanoliposomes and administered intraperitoneally (IP) at a dose of 150 mg/kg
per mouse, biweekly. Paclitaxel was administered IP once a week at a dose of
100 mg per mouse for HeyA8 and 75 mg per mouse for SKOV3ip1. Mice were
treated for 3 to 4 weeks and all treatment groups were sacrificed and necrop-
sied when any single group became moribund and assayed for tumor weight.
Detailed additional methods are available as Supplemental Information.120 Cancer Cell 18, 109–121, August 17, 2010 ª2010 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, four tables, and three movies and can be found with this article
online at doi:10.1016/j.ccr.2010.06.018.ACKNOWLEDGMENTS
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